Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
NCT02393378 · Takeda · PHASE2 · terminated · last registry update 2019-02-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Strategic decision - to understand data from psoriasis study - NCT02129777 and wait for results of formal proof of concept study - NCT02379091.” | – | Registry record, Takeda |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-10-22Phase 3 first posted: GlaxoSmithKline, GSK3196165 (Otilimab) + Sarilumab (NCT04134728)
- 2019-06-10Phase 3 first posted: GlaxoSmithKline, GSK3196165 (Otilimab) + Tofacitinib 5 mg (NCT03980483)
- 2019-06-03Phase 3 first posted: GlaxoSmithKline, GSK3196165 (Otilimab) + Tofacitinib (NCT03970837)
- 2019-04-04Results posted on the registry: GlaxoSmithKline, GSK3196165 + MTX (NCT02504671)
- 2018-12-14Results posted on the registry: GlaxoSmithKline, GSK3196165 + Placebo (NCT02683785)
- 2018-11-16Results posted on the registry: GlaxoSmithKline, GSK3196165 + Placebo (NCT02799472)
- 2018-09-14Results posted on the registry: Takeda, Namilumab + Placebo (NCT02379091)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision